Growth Vs. Value: Capturing Complementary Factor Exposure

In 2023 and 2024, WisdomTree U.S. Quality Growth Fund significantly outperformed SPY, capturing upside in innovation-driven ...
ascopubs.org

Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...